jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2021-13-3-55-61jofin-1240Research ArticleОригинальное исследованиеOriginal ResearchДиагностические маркеры в аспекте развития ВИЧ-энцефалопатии у детейDiagnostic markers in the aspect of the development of HIV-encephalopathy in childrenСаидходжаеваС. Н.SaidkhodjaevaS. N.

Саидходжаева Саида Набиевна — доцент кафедры неврологии, детской неврологии и медицинской генетики ТашПМИ, кандидат медицинских наук.

Ташкент.

Тел.: +998-71-260-36-58

Tashkent.

dr.saida25@gmail.comМаджидоваЕ. Н.MadjidovaE. N.

Маджидова Ёкутхон Набиевна — профессор, заведующая кафедрой неврологии, детской неврологии и медицинской генетики ТашПМИ, доктор медицинских наук.

Ташкент.

Тел.: +998-71-260-36-58

Tashkent.

madjidova1@yandex.ruЮлдашевК. Х.YuldashevK. Kh.

Юлдашев Кахрамон Халдарович. — директор Республиканского центра по борьбе со СПИДом, доктор медицинских наук, профессор.

Ташкент.

Тел.: +998-909-95-59-57

Tashkent.

dr.saida25@gmail.comТашкентский педиатрический медицинский институтУзбекистанTashkent Pediatric Medical InstituteUzbekistanРеспубликанский центр по борьбе со СПИДомУзбекистанRepublican AIDS CenteUzbekistan2021081020211335561Copyright © Саидходжаева С.Н., Маджидова Е.Н., Юлдашев К.Х., 20212021Саидходжаева С.Н., Маджидова Е.Н., Юлдашев К.Х.Saidkhodjaeva S.N., Madjidova E.N., Yuldashev K.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1240Цель

Цель: оценить у детей диагностические маркеры развития ВИЧ-энцефалопатии различной степени выраженности.

Материалы и методы

Материалы и методы: в исследование были включены. 260 детей (153 мальчика — 58,85% и 107 девочек —41,7%), имеющих ВИЧ-позитивный статус и принимающих антиретровирусную терапию по индивидуально подобранной схеме не менее 6 месяцев. У всех детей, включенных в исследование, были обнаружены признаки ВИЧ-энцефалопатии. Диагностические маркеры интерпретировались по концентрации ИЛ-6, ИЛ-10, ФНО-альфа, С-реактивного белка, С3, С4 компонентов комплемента (иммунонефелометрический анализ).

Результаты

Результаты: изучение маркеров у детей с ВИЧ-энцефалопатией обнаружило, что концентрация ФНО-альфа и ИЛ-6 была увеличена по сравнению с референтными значениями (12,67±0,25 пг/мл и 23,04±0,64 пг/мл соответственно, при референтных значениях — менее 8,1 пг/мл и 7пг/мл соответственно), а концентрация ИЛ-10 — снижена (5,93±0,10 пг/мл при референтном, значении — более 9,1 пг/мл). В ходе исследования был проведен анализ предикторной значимости различных параметров, в аспекте развития симптомной ВИЧ-энцефалопатии. Проведен сравнительный анализ концентрации маркеров, а также определена частота встречаемости симптомной ВИЧ-энцефалопатии в зависимости от диагностической концентрации маркера.

Заключение

Заключение: максимальная предикторная значимость в аспекте развития симптомной ВИЧ-энцефалопатии обнаружена у провоспалительных цитокинов: увеличение концентрации ИЛ-6 выше 19,6 пг/мл ассоциируется с увеличением риска развития симптомной ВИЧ-энцефалопатии в 9,14 раза, увеличение концентрации ФНО-альфа выше 12,5 пг/мл — в 4,07 раза (p<0,001 для обоих факторов).

The aim of the study was to evaluate the diagnostic markers in children with HIV —encephalopathy (HIVE) with varying degrees of severity.

Material and methods of research: The study included 260 children (153 boys — 58.85% and 107 girls —41.7%) with HIV-positive status and receiving antiretroviral therapy according to an individually selected scheme for at least 6 months. All children included in the study showed signs of HIV encephalopathy. The activity response was assessed by the concentration of IL-6, IL-10, TNF-alpha, C-reactive protein, C3, C4 components of the complement (immunofelometric analysis).

Results

Results: The study of the activity response in children with HIV encephalopathy found that the concentration of TNF —alpha and IL-6 were increased, compared, to the reference values (12.67±0.25 PG/ml and 23.04±0.64 PG/ml, respectively, with reference values of less than 8.1 PG/ml and 7pg/ml, respectively), and the concentration of IL-10 was reduced (5.93±0.10 PG/ml with a reference value of more than 9.1 PG/ml). The study analyzed the predictor significance of various parameters response in the aspect of the development of symptomatic HIV- encephalopathy. A comparative analysis of the concentration markers was performed, and the incidence of symptomatic HIV —encephalopathy was determined depending on the diagnostic concentration of the diagnostic marker. This finding is probably explained by the effector role of systemic inflammation in the development of damage to the Central nervous system.

Conclusion

Conclusion. The maximum predictor significance in the aspect of the development of symptomatic HIV -encephalopathy was found in proinflammatory cytokines: an increase in IL-6 concentration above 19.6 PG / ml is associated with an increase in the risk of developing symptomatic HIV encephalopathy by 9.14 times, and an increase in TNF -alpha concentration above 12.5 PG/ml by 4.07 times (p<0.001 for both factors).

ВИЧ-инфекцияВИЧ-энцефалопатияфактор некроза опухоли-альфаинтерлейкин-6интерлейкин-10комплементдетиHIV -infectionHIV -encephalopathytumor necrosis factor-alphainterleukin-6interleukin-10complementchildrenReferencesUNAIDS. Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. Global AIDS Update 2016.UNAIDS. Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2016. Global AIDS Update 2016.UNAIDS. UNAIDS, ed Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2017. UNAIDS Data 2017UNAIDS. UNAIDS, ed Global AIDS Update. Geneva: Joint United Nations Programme on HIV/AIDS; 2017. UNAIDS Data 2017Foster CJ, Biggs RL, Melvin D, et al: Neurodevelopmental outcomes in children with HIV infection under 3 years of age. Dev Med Child Neurol 48:677-682, 2006Foster CJ, Biggs RL, Melvin D, et al: Neurodevelopmental outcomes in children with HIV infection under 3 years of age. Dev Med Child Neurol 48:677-682, 2006Chiriboga CA, Fleishman S, Champion S, et al: Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr 146:402-407, 2005Chiriboga CA, Fleishman S, Champion S, et al: Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr 146:402-407, 2005Nachman SA, Chernoff M, Gona P, et al: Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med 163:164-171. http://dx.doi.org/10.1001/archpedi.163.2.164. [Erratum in: Arch Pediatr Adolesc Med. 2009 Apr;163(4):364]Nachman SA, Chernoff M, Gona P, et al: Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med 163:164-171. http://dx.doi.org/10.1001/archpedi.163.2.164. [Erratum in: Arch Pediatr Adolesc Med. 2009 Apr;163(4):364]Patel K, Ming X, Williams PL, et al: Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 23:1893-1894-1901, 2009Patel K, Ming X, Williams PL, et al: Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 23:1893-1894-1901, 2009Shanbhag MC, Rutstein RM, Zaoutis T, et al: Neurocognitive functioning in pediatric human immunodeficiency virus infection: Effects of combined therapy. Arch Pediatr Adolesc Med 159:651-656, 2005Shanbhag MC, Rutstein RM, Zaoutis T, et al: Neurocognitive functioning in pediatric human immunodeficiency virus infection: Effects of combined therapy. Arch Pediatr Adolesc Med 159:651-656, 2005Laughton B, Cornell M, Grove D, et al: Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 26:1685, 2012Laughton B, Cornell M, Grove D, et al: Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 26:1685, 2012Puthanakit T, Ananworanich J, Vonthanak S, et al: Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: The PREDICT neurodevelopmental study. Pediatr Infect Dis J 32:501-508. http://dx.doi.org/10.1097/INF.0b013e31827fb19d.Puthanakit T, Ananworanich J, Vonthanak S, et al: Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: The PREDICT neurodevelopmental study. Pediatr Infect Dis J 32:501-508. http://dx.doi.org/10.1097/INF.0b013e31827fb19d.Smith L, Adnams C, Eley B: Neurological and neurocognitive function of HIV-infected children on antiretroviral therapy. S Afr J Child Health 2:108-118, 2008Smith L, Adnams C, Eley B: Neurological and neurocognitive function of HIV-infected children on antiretroviral therapy. S Afr J Child Health 2:108-118, 2008Whitehead N, Potterton J, Coovadia A: The neurodevelopment of HIV-infected infants on HAART compared to HIV-exposed but uninfected infants. AIDS Care 26:497-504, 2013Whitehead N, Potterton J, Coovadia A: The neurodevelopment of HIV-infected infants on HAART compared to HIV-exposed but uninfected infants. AIDS Care 26:497-504, 2013Wood SM, Shah SS, Steenhoff AP, et al: The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS 23:1859-1865. http://dx.doi.org/10.1097/QAD.0b013e32832d924f.Wood SM, Shah SS, Steenhoff AP, et al: The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS 23:1859-1865. http://dx.doi.org/10.1097/QAD.0b013e32832d924f.Campbell T: A review of the psychological effects of vertically acquired HIV infection in infants and children. Br J Health Psychol 2:1-13, 2011Campbell T: A review of the psychological effects of vertically acquired HIV infection in infants and children. Br J Health Psychol 2:1-13, 2011Govender R, Eley B, Walker K, et al: Neurologic and neurobehavioral sequelae in children with human immunodeficiency virus (HIV-1) infection. J Child Neurol 26:1355-1364, 2011Govender R, Eley B, Walker K, et al: Neurologic and neurobehavioral sequelae in children with human immunodeficiency virus (HIV-1) infection. J Child Neurol 26:1355-1364, 2011Willen EJ: Neurocognitive outcomes in pediatric HIV. Ment Retard Dev Disabil Res Rev 12:223-228, 2006Willen EJ: Neurocognitive outcomes in pediatric HIV. Ment Retard Dev Disabil Res Rev 12:223-228, 2006Pearson DA, McGrath NM, Nozyce M, et al: Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team. Pediatrics 106:E76, 2000Pearson DA, McGrath NM, Nozyce M, et al: Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team. Pediatrics 106:E76, 2000CDC1994 revised classification system for HIV infection in children less than 13 years of age. MMWR Recomm Rep 443:1-10, 1994CDC1994 revised classification system for HIV infection in children less than 13 years of age. MMWR Recomm Rep 443:1-10, 1994Walker SP, Wachs TD, Grantham-McGregor S, et al: Inequality in early childhood: Risk and protective factors for early child development. Lancet 378:1325-1338, 2011Walker SP, Wachs TD, Grantham-McGregor S, et al: Inequality in early childhood: Risk and protective factors for early child development. Lancet 378:1325-1338, 2011Langerak NG, du Toit J, Burger M, et al: Spastic diplegia in children with HIV encephalopathy: First description of gait and physical status. Dev Med Child Neurol http://dx.doi.org/10.1111/dmcn.12319. [Epub ahead of print].Langerak NG, du Toit J, Burger M, et al: Spastic diplegia in children with HIV encephalopathy: First description of gait and physical status. Dev Med Child Neurol http://dx.doi.org/10.1111/dmcn.12319. [Epub ahead of print].Le Doare K, Bland R, Newell M: Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 130: e1326-e1344, 2012Le Doare K, Bland R, Newell M: Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics 130: e1326-e1344, 2012Abubakar A, Van Baar A, Van de Vijver FJ, et al: Paediatric HIV and neurodevelopment in sub-Saharan Africa: A systematic review. Trop Med Int Health 13:880-887, 2008Abubakar A, Van Baar A, Van de Vijver FJ, et al: Paediatric HIV and neurodevelopment in sub-Saharan Africa: A systematic review. Trop Med Int Health 13:880-887, 2008Van Rie A, Mupuala A, Dow A: Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Dem-ocratic Republic of the Congo. Pediatrics 122:e123-e128, 2008Van Rie A, Mupuala A, Dow A: Impact of the HIV/AIDS epidemic on the neurodevelopment of preschool-aged children in Kinshasa, Dem-ocratic Republic of the Congo. Pediatrics 122:e123-e128, 2008Bloch M, Kamminga J, Jayewardene A, et al. : A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis. 2016;63(5):687-693. http://dx.doi.org/10.1093/cid/ciw399 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Bloch M, Kamminga J, Jayewardene A, et al. : A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis. 2016;63(5):687-693. http://dx.doi.org/10.1093/cid/ciw399 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Dahl V, Peterson J, Fuchs D, et al. : Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251-2258. http://dx.doi.org/10.1097/QAD.0000000000000400 [PMC free article] [PubMed] [Cross-Ref] [Google Scholar]Dahl V, Peterson J, Fuchs D, et al. : Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251-2258. http://dx.doi.org/10.1097/QAD.0000000000000400 [PMC free article] [PubMed] [Cross-Ref] [Google Scholar]

The authors declare that there are no conflicts of interest present.